评价焦点性不可逆电穿孔（IRE）用于介于短期和中期随访的放射复发前列腺癌（PCa）的安全、肿瘤学和生活质量（QoL）成果。本文是对在2013年12月至2022年2月期间接受IRE治疗的经活检证实的放射复发PCa患者在至少6个月的随访中的单中心系列研究，其中包括了6个月的磁共振成像，和12个月的标准经会阴饱和模板活检。进一步的活检由连续成像或前列腺特异性抗原（PSA）水平怀疑指引。使用验证问卷衡量功能结果。在活检中，任何国际泌尿学病理学会（ISUP）评分≥2被定义为显著的局部复发。进展自由生存是指在成像或模板活检中没有局部或系统性疾病迹象，或根据生化复发的菲尼克斯标准。 对74例放射复发PCa患者（年龄中位数69岁，PSA水平中位数5.4 ng / mL，76％的ISUP评分为2/3）进行最终分析，随访的中位数（范围）为48（27-68）个月。出现一个直肠瘘，并且8名患者出现了尿道脱垂，经导尿道切除术治疗后得到了解决。在回答问卷的患者中（30/74，41％），93％（28/30）在12个月的随访中保持了尿控制，23％（7/30）在随访期内保持了勃起功能。57名患者（77％）实现了局部控制，无需进一步治疗。经活检检查的41名（55％）患者接受了随访模板活检，现场复发发生在7％（3/41）患者身上，越野复发在15％的患者身上（6/41）。无转移生存率为91％（67/74），转移中位（四分位）时间为8（5-27）个月。Kaplan-Meier估计的5年进展自由生存率为60％。 这些介于短期和中期的安全、肿瘤学和QoL成果数据验证了较小系列的结果，并显示了救治焦点性IRE在放射复发PCa患者中实现安全肿瘤学控制的能力。©2023作者。BJU International由约翰威立出版社代表BJU International出版。

To evaluate the safety, and short to mid-term oncological and quality-of-life (QoL) outcomes of focal irreversible electroporation (IRE) for radio-recurrent prostate cancer (PCa) at a median follow-up of 4 years.This was a single-centre series of men with biopsy-proven radio-recurrent PCa treated with IRE between December 2013 and February 2022, with a minimum follow-up of 6 months. Follow-up included magnetic resonance imaging at 6 months, and standard transperineal saturation template biopsies at 12 months. Further biopsies were guided by suspicion on serial imaging or prostate-specific antigen (PSA) levels. Validated questionnaires were used to measure functional outcomes. Significant local recurrence was defined as any International Society of Urological Pathology (ISUP) score ≥ 2 on biopsies. Progression-free survival was defined as no signs of local or systemic disease on either imaging or template biopsies, or according to the Phoenix criteria for biochemical recurrence.Final analysis was performed on 74 men with radio-recurrent PCa (median age 69 years, median PSA level 5.4 ng/mL, 76% ISUP score 2/3). The median (range) follow-up was 48 (27-68) months. One rectal fistula occurred, and eight patients developed urethral sloughing that resolved with transurethral resection. Among patients who returned questionnaires (30/74, 41%), 93% (28/30) had preserved urinary continence and 23% (7/30) had sustained erectile function at 12-month follow-up. Local control was achieved in 57 patients (77%), who needed no further treatment. Biopsy diagnosed 41(55%) patients received follow up template biopsies, in-field recurrences occurred in 7% (3/41), and out-field recurrences occurred in 15% of patients (6/41). The metastasis-free survival rate was 91% (67/74), with a median (interquartile range) time to metastases of 8 (5-27) months. The Kaplan-Meier estimated 5-year progression-free survival rate was 60%.These short- to mid-term safety, oncological and QoL outcome data endorse results from smaller series and show the ability of salvage focal IRE to safely achieve oncological control in patients with radio-recurrent PCa.© 2023 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International.